Shots: The approval is based on P-III ECHELON-1 study result assessing Adcetris + AVD (adriamycin, vinblastine and dacarbazine) vs ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) in patients with previously untreated CD30-positive and has met its 1EPs with 23% reduction in risk progression & improvement in PFS According to 2009 deal b/w Seattle Genetics & Takeda […]Read More
